NLR与慢性阻塞性肺疾病并肺癌一线化疗疗效的关系
Relationship between NLR and Efficacy of First-Line Chemotherapy for Chronic Obstructive Pulmonary Disease with Lung Cancer
摘要: 目的:本研究旨在探讨化疗开始前外周血中性粒细胞/淋巴细胞比值(neutrophil-to-lymphocyte ratio, NLR)对慢性阻塞性肺疾病(chronic obstructive pulmonary disease,简称:慢阻肺)并肺癌患者一线化疗疗效的预测作用。方法:回顾性分析2014年01月~2020年01月于青岛市市立医院呼吸与危重症医学科住院治疗的66例慢性阻塞性肺疾病并肺癌患者,并以NLR的中位数3.95为依据,划为低NLR组和高NLR组,分析入组患者的病历资料和一线化疗疗效。结果:低NLR组和高NLR组患者在年龄、性别、吸烟史、TNM分期、组织病理类型和一线化疗方案上,差异无统计学意义(P > 0.05)。低NLR组近期化疗疗效明显优于高NLR组,差异有统计学意义(P < 0.05)。结论:化疗开始前外周血NLR与进行一线化疗方案治疗的慢性阻塞性肺疾病并肺癌患者的近期化疗疗效密切相关,外周血NLR有可能成为预测慢性阻塞性肺疾病并肺癌一线化疗效果的理想指标。
Abstract: Object: The purpose of this study was to investigate the predictive value of neutrophil to lymphocyte ratio (NLR) in patients with chronic obstructive pulmonary disease (COPD) and lung cancer before chemotherapy. Methods: From January 2014 to January 2020, 66 patients with chronic obstructive pulmonary disease and lung cancer in the Department of Respiratory and Critical Care Medicine of Qingdao Municipal Hospital were retrospectively analyzed. According to the median NLR of 3.95, they were divided into the high NLR group and the low NLR group. Results: There was no significant difference in age, gender, smoking history, TNM stage, histopathological type and first-line chemotherapy between the high NLR group and the low NLR group (P > 0.05). The short-term chemotherapy effect of the low NLR group was significantly better than that of the high NLR group (P < 0.05). Conclusion peripheral blood NLR before chemotherapy is closely related to the short-term chemotherapy efficacy of patients with COPD and lung cancer treated with first-line chemotherapy. Peripheral blood NLR may be an ideal index to predict the effect of first-line chemotherapy for COPD and lung cancer.
文章引用:张杰, 叶兴, 段传洲. NLR与慢性阻塞性肺疾病并肺癌一线化疗疗效的关系[J]. 临床医学进展, 2021, 11(1): 403-409. https://doi.org/10.12677/ACM.2021.111057

参考文献

[1] Wang, C., Xu, J., Yang, L., et al. (2018) Prevalence and Risk Factors of Chronic Obstructive Pulmonary Disease in China (the China Pulmonary Health [CPH] Study): A National Cross-Sectional Study. The Lancet, 391, 1706-1717. [Google Scholar] [CrossRef
[2] McGregor, H.C., Short, M.A., McWilliams, A., et al. (2017) Real-Time Endoscopic Raman Spectroscopy for in Vivo Early Lung Cancer Detection. Journal of Biophotonics, 10, 98-110. [Google Scholar] [CrossRef] [PubMed]
[3] 中国肿瘤临床与康复编辑部. 2017年中国最新癌症数据[J]. 中国肿瘤临床与康复, 2017, 24(6): 760.
[4] 中华医学会, 中华医学会肿瘤学分会, 中华医学会杂志社. 中华医学会肺癌临床诊疗指南(2018版) [J]. 中华肿瘤杂志, 2018, 40(12): 935-964.
[5] Zeneyedpour, L., Dekker, L.J.M., van Sten-van, T., Hoff, J.J.M., et al. (2019) Neoantigens in Chronic Obstructive Pulmonary Disease and Lung Cancer: A Point of View. Proteomics Clinical Applications, 13, e1800093. [Google Scholar] [CrossRef] [PubMed]
[6] 徐汉章. 慢性阻塞性肺疾病合并肺癌患者肺功能、免疫功能及营养状态研究[J]. 中国现代药物应用, 2020, 14(6): 46-47.
[7] Templeton, A.J., McNamara, M.G., Seruga, B., et al. (2014) Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. Journal of the National Cancer Institute, 106, dju124. [Google Scholar] [CrossRef] [PubMed]
[8] Diem, S., Schmid, S., Krapf, M., et al. (2017) Neutrophil-to-Lymphocyteratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as Prognostic Markers in Patients with Nonsmall Cell Lung Cancer (NSCLC) Treated with Nivolumab. Lung Cancer, 111, 176-181. [Google Scholar] [CrossRef] [PubMed]
[9] Detterbeck, F.C., Boffa, D.J. and Tanoue, L.T. (2009) The New Lung Cancer Staging System. Chest, 136, 260-271. [Google Scholar] [CrossRef] [PubMed]
[10] Nishino, M., Jackman, D.M., Hatabu, H., et al. (2010) New Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines for Advanced Nonsmall Cell Lung Cancer: Comparison with Original RECIST and Impact on Assessment of Tumor Response to Targeted Therapy. AJR American Journal of Roentgenology, 195, W221-W228. [Google Scholar] [CrossRef
[11] Sears, C.R. (2019) DNA Repair as an Emerging Target for COPD-Lung Cancer Overlap. Respiratory Investigation, 57, 111-121. [Google Scholar] [CrossRef] [PubMed]
[12] Koshiol, J., Rotunno, M., Consonni, D., et al. (2009) Chronic Obstructive Pulmonary Disease and Altered Risk of Lung Cancer in a Population-Based Case-Control Study. PLoS ONE, 4, e7380. [Google Scholar] [CrossRef] [PubMed]
[13] 王学林. 慢性阻塞性肺疾病合并肺癌的临床特点分析[J]. 临床医学, 2019, 39(2): 27-28.
[14] 王丹, 庞敏. 慢性阻塞性肺疾病合并肺癌的临床特征分析[J]. 临床肺科杂志, 2019, 24(6): 1082-1085.
[15] 胡洁, 白春学. 肺癌的规范化治疗[J]. 内科急危重症杂志, 2014, 20(5): 294-298.
[16] Sekine, Y., Katsura, H., Koh, E., et al. (2012) Early Detection of COPD Is Important for Lung Cancer Surveillance. European Respiratory Journal, 39, 1230. [Google Scholar] [CrossRef] [PubMed]
[17] Durham, A.L. and Adcock, I.M. (2015) The Relationship between COPD and Lung Cancer. Lung Cancer, 90, 121-127. [Google Scholar] [CrossRef] [PubMed]
[18] Chen, L., Kong, X., Yan, C., et al. (2020) The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer. OncoTargets and Therapy, 13, 1397-1412. [Google Scholar] [CrossRef
[19] Miyamoto, R., Inagawa, S., Sano, N., et al. (2018) The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts Short-Term and Long-Term Outcomes in Gastric Cancer Patients. European Journal of Surgical Oncology, 44, 607-612. [Google Scholar] [CrossRef] [PubMed]
[20] Zhang, J., Zhang, H.Y., Li, J., et al. (2017) The Elevated NLR, PLR and PLT May Predict the Prognosis of Patients with Colorectal Cancer: A Systematic Review and Meta-Analysis. Oncotarget, 8, 68837-68846. [Google Scholar] [CrossRef] [PubMed]
[21] Iimori, N., Kashiwagi, S., Asano, Y., et al. (2018) Clinical Significance of the Neutrophil-to-Lymphocyte Ratio in Endocrine Therapy for Stage IV Breast Cancer. In Vivo, 32, 669-675. [Google Scholar] [CrossRef] [PubMed]
[22] Yao, Y., Yuan, D., Liu, H., et al. (2013) Pretreatment Neutrophil to Lymphocyte Ratio Is Associated with Response to Therapy and Prognosis of Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy. Cancer Immunology, Immunotherapy, 62, 471-479. [Google Scholar] [CrossRef] [PubMed]
[23] Peng, B., Wang, Y.H., Liu, Y.M., et al. (2015) Prognostic Significance of the Neutrophil to Lymphocyte Ratio in Patients with Non-Small Cell Lung Cancer: A Systemic Review and Meta-Analysis. International Journal of Clinical and Experimental Medicine, 8, 3098-3106.
[24] Botta, C., Barbieri, V., Ciliberto, D., et al. (2013) Systemic Inflammatory Status at Baseline Predicts Bevacizumab Benefit in Advanced Non-Small Cell Lung Cancer Patients. Cancer Biology & Therapy, 14, 469-475. [Google Scholar] [CrossRef] [PubMed]
[25] 李曦颖, 黄礼年. 动态监测NLR、PLR变化与晚期肺腺癌一线化疗疗效及预后关系[J]. 蚌埠医学院学报, 2020, 45(11): 1486-1490.
[26] Li, X., Zeng, W.H., Zhou, Y.Q., et al. (2019) Neutrophil-to-Lymphocyte Ratio Predicted Long-Term Chemotherapy Benefits in Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer Patients without Sensitive Mutations. OncoTargets and Therapy, 12, 8779-8787. [Google Scholar] [CrossRef
[27] Vaguliene, N., Zemaitis, M., Lavinskiene, S., et al. (2013) Local and Systemic Neutrophilic Inflammation in Patients with Lung Cancer and Chronic Obstructive Pulmonary Disease. BMC Immunology, 14, 36. [Google Scholar] [CrossRef] [PubMed]
[28] 易福梅, 顾阳春, 陈森, 刘燕娥, 尹文琤, 张煜, 曹宝山. 治疗前后NLR和PLR对进展期非小细胞肺癌一线化疗疗效及预后的预测价值[J]. 中国肺癌杂志, 2018, 21(6): 481-492.